Jack W. Callicutt
Known title: Chief Financial OfficerCIK: 0001266773
Associated companies
Transaction History
| GALT | ▼ Sell | Open Market | 20,354 | $75K | 1/6/2026 | View on chart |
| GALT | ▼ Sell | Open Market | 25,732 | $100K | 1/5/2026 | View on chart |
| GALT | ▲ Buy | Option Exercise | 60,000 | $0 | 1/2/2026 | View on chart |
| GALT | ▼ Sell | Open Market | 13,914 | $58K | 1/2/2026 | View on chart |
| GALT | ▼ Sell | Open Market | 18,210 | $113K | 11/18/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 28,100 | $56K | 11/18/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 28,100 | $175K | 11/18/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 18,210 | $20K | 11/18/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 9,586 | $19K | 11/17/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 9,586 | $58K | 11/17/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 19,701 | $22K | 11/17/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 19,701 | $119K | 11/17/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 2,323 | $3K | 11/17/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 2,323 | $14K | 11/17/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 1,675 | $2K | 11/10/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 1,736 | $10K | 11/10/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 1,675 | $10K | 11/10/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 1,736 | $2K | 11/10/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 1,880 | $4K | 11/10/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 1,880 | $11K | 11/10/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 200 | $396 | 11/5/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 200 | $1K | 11/5/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 200 | $222 | 11/5/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 200 | $1K | 11/5/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 200 | $344 | 11/5/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 200 | $1K | 11/5/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 10,741 | $65K | 11/4/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 10,741 | $18K | 11/4/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 8,974 | $10K | 11/4/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 8,974 | $54K | 11/4/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 8,914 | $54K | 11/4/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 8,914 | $18K | 11/4/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 1,300 | $3K | 11/3/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 1,300 | $8K | 11/3/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 1,260 | $1K | 11/3/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 1,250 | $2K | 11/3/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 1,250 | $8K | 11/3/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 1,260 | $8K | 11/3/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 8,706 | $12K | 9/12/2025 | View on chart |
| GALT | ▼ Sell | Open Market | 8,706 | $56K | 9/12/2025 | View on chart |
| GALT | ▲ Buy | Option Exercise | 40,000 | $0 | 12/23/2024 | View on chart |
| GALT | ▼ Sell | Open Market | 40,000 | $35K | 12/23/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 4,000 | $5K | 11/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Galectin Clears Balance Sheet with $105M Debt Conversion
Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.
Galectin Clears Balance Sheet with $105M Debt Conversion. Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.